Tablet & Teva Block Sun As Generic Competition For Wyeth’s Effexor XR
Executive Summary
Wyeth is anticipating it will be able to block entry of Sun Pharmaceuticals' generic version of Effexor XR because of the brand firm's existing deal with first-to-file Teva and the alternate venlafaxine dosage form that Sun is using in its ANDA
You may also be interested in...
Wyeth Finally Cleared For Pristiq Lift-Off, But With Lower Dose
Approval of Wyeth's Pristiq (desvenlafaxine) comes at the lower dose that was submitted late in the review process and with a request for a postmarketing study to determine if even lower doses would be effective
Wyeth Finally Cleared For Pristiq Lift-Off, But With Lower Dose
Approval of Wyeth's Pristiq (desvenlafaxine) comes at the lower dose that was submitted late in the review process and with a request for a postmarketing study to determine if even lower doses would be effective
Wyeth Looks To Specialty Markets As Generics Challenge Current Model
Wyeth's R&D pipeline is evolving the firm toward more specialized areas as several of its blockbuster products face patent expirations and generic challenges